PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
View analysts' price targets and recommendations, and compare them with competitors.
$11.07
Analysts expect the stock price to increase by 521.91%.
Buy
Positive consensus among analysts.
Analyze analyst forecasts for the company and compare them with competitors.
9.68M
Worse than TGTX's estimated revenue of 541.17M.
-1.93M
Better than TGTX's estimated ebitda of -420.85M.
-1.38
Worse than TGTX's estimated eps of 0.96.
-41.62M
Worse than TGTX's estimated net income of 157.49M.
-1.93M
Better than TGTX's estimated ebit of -421.04M.
358.54M
Better than TGTX's estimated sg&a expense of 107.33B.
Analyze DCF forecasts for the company and compare them with competitors.
No Data
No DCF data available for this metric in the selected year.
-100.00%
Worse than TGTX's revenue growth rate of 35.41%.
-37.43M
Better than TGTX's ebitda of -246.05M.
100.00%
Better than TGTX's ebitda margin of -77.77%.
-38.24M
Better than TGTX's ebit of -246.17M.
100.00%
Better than TGTX's ebit margin of -77.80%.
811.00K
Better than TGTX's depreciation of 143.05M.
72.90M
Worse than TGTX's total cash of 312.02M.
100.00%
Better than TGTX's cash as percentage of revenue of 98.62%.
No Data
No DCF data available for this metric in the selected year.
100.00%
Worse than TGTX's receivables as percentage of revenue of 8.53%.
No Data
No DCF data available for this metric in the selected year.
100.00%
Worse than TGTX's inventories as percentage of revenue of -16.59%.
No Data
No DCF data available for this metric in the selected year.
100.00%
Worse than TGTX's payables as percentage of revenue of 63.29%.
-11.00K
Worse than TGTX's capital expenditure of -121.93M.
100.00%
Worse than TGTX's capex as percentage of revenue of -38.54%.
4.99%
Better than TGTX's weighted average cost of capital (wacc) of 14.67%.
5.02%
Better than TGTX's cost of equity of 14.75%.
4.08%
Better than TGTX's cost of debt of 11.39%.
-0.23
Better than TGTX's beta of 2.19.
30.07M
Better than TGTX's diluted shares outstanding of 148.51M.
1.57M
Better than TGTX's total debt of 110.80M.
49.31M
Worse than TGTX's total equity of 4.61B.
50.89M
Worse than TGTX's total capital of 4.72B.
3.09%
Worse than TGTX's debt weighting of 2.35%.
96.91%
Worse than TGTX's equity weighting of 97.65%.
-38.24M
Better than TGTX's ebiat of -244.70M.
-45.40M
Worse than TGTX's unlevered free cash flow of 54.65M.
2.00%
Equal to TGTX's long-term growth rate of 2.00%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
-71.33M
Better than TGTX's net debt of 17.86M.
71.33M
Better than TGTX's equity value of -3.10B.
2.37
Better than TGTX's equity value per share of -20.88.